ReviewSeminars in immunopathology2013
Resolution of inflammation as a novel chemopreventive strategy.
Review in Seminars in immunopathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 49 citations in OpenAlex.
- Elastic Cytomatrix Dynamics Influences Metabolic Rate and Tumor Microenvironment Formation.Cancers · 2025Review
- Renal dysfunction as a predictor of recurrence and prognosis in colorectal cancer.Frontiers in oncology · 2025Article
- Progranulin: A promising biomarker and therapeutic target for fibrotic diseases.Acta pharmaceutica Sinica. B · 2024Review
- Cytokine concentration in peripheral blood of patients with colorectal cancer.Frontiers in immunology · 2023Article
- The effect ofArchives of medical science : AMS · 2022Review
- Inhibitory Effect ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Lipoxins and Resolvins in Patients With Pancreatic Cancer: A Preliminary Report.Frontiers in oncology · 2021Article
- Mediation of antiinflammatory effects of Rg3-enriched red ginseng extract from Korean Red Ginseng via retinoid X receptor α-peroxisome-proliferating receptor γ nuclear receptors.Journal of ginseng research · 2019Article
- Aspirin-triggered lipoxin A4 attenuates lipopolysaccharide-induced acute lung injury by inhibiting activation of mitogen-activated protein kinases and NF-κB in mice.International journal of clinical and experimental pathology · 2018Article
- Zileuton suppresses cholangiocarcinoma cell proliferation and migration through inhibition of the Akt signaling pathway.OncoTargets and therapy · 2018Article
- Tacrolimus downregulates inflammation by regulating pro‑/anti‑inflammatory responses in LPS‑induced keratitis.Molecular medicine reports · 2017Article
- Advances in Understanding of Penile Carcinogenesis: The Search for Actionable Targets.International journal of molecular sciences · 2017Review
- Chemopreventive and Chemotherapeutic Effects of Fish Oil derived Omega-3 Polyunsaturated Fatty Acids on Colon Carcinogenesis.Clinical nutrition research · 2017Review
- Dendritic cells expressing immunoreceptor CD300f are critical for controlling chronic gut inflammation.The Journal of clinical investigation · 2017Article
- Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer.Oncotarget · 2017Article
- Resolution of Cochlear Inflammation: Novel Target for Preventing or Ameliorating Drug-, Noise- and Age-related Hearing Loss.Frontiers in cellular neuroscience · 2017Review
- The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.Seminars in immunology · 2015Review
- Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits.Gastroenterology · 2015Review
- Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis.PloS one · 2014Article
- Molecular research in penile cancer-lessons learned from the past and bright horizons of the future?International journal of molecular sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute inflammation, a physiologic response to protect cells from microbial infection and other noxious stimuli, is automatically terminated by endogenous anti-inflammatory and pro-resolving mediators to restore homeostatic conditions. However, if timely resolution of inflammation is failed, inflammation persists and can progress to a chronic inflammation which has long been thought as a predisposing factor to carcinogenesis. Excessive and pathologic inflammation causes DNA damage, genomic instability, epigenetic dysregulation, and alteration of intracellular signaling, all of which are involved in neoplastic transformation. To prevent chronic inflammation and resulting inflammation-promoted cancer development, understanding the process that resolves inflammation is essential. Resolution of inflammation is an active coordinated process regulated by distinct anti-inflammatory and pro-resolving endogenous lipid mediators, such as resolvins and lipoxins. The role of pro-inflammatory signaling in carcinogenesis has become more and more evident and well characterized, but the potential role of pro-resolving mediators in cancer prevention remains still elusive. In searching for an efficacious way to prevent chronic inflammation-associated cancer, the pro-resolving signal transduction pathways and their regulators should be unraveled.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.